Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Secondary CNS lymphoma: recent data and future approaches

Kate Cwynarski • 22 Jun 2020
EHA 2020
CNS Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel MATRIX Tisagenlecleucel
IELSG 42

Kate Cwynarski, MD, PhD, University College Hospital, London, UK, review recent data in secondary CNS lymphoma presented at ASH 2019, BSH 2020 and EHA 2020. Dr Cwynarski specifically discusses the IELSG 42 study evaluating the MARIETTA regimen in CNS lymphoma patients. Historically, CNS lymphoma has had poor outcomes, however, it is hoped that with larger, randomized trials as well as novel treatment approaches, there may be improved results in patients with this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kate Cwynarski

7:52
Highlights in T-cell lymphoma: unmet needs, clinical trial updates, and future outlooks
Kate Cwynarski et al. • 12 Dec 2022
3:31
Upcoming trials and agents in T-cell lymphoma
Gloria Iacoboni et al. • 10 Jun 2022
7:50
Updates from the lymphoma & CLL session: clinical trials, novel agents, and more
Andrew Davies et al. • 4 Apr 2022
4:24
High-dose methotrexate as CNS prophylaxis in DLBCL
Kate Cwynarski • 16 Jul 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals